Dr. Gaerolwe Masheto

Dr. Gaerolwe Masheto started working at Botswana Harvard Health Partnership (BHP) Clinical Trial Unit (CTU) in 2011 as a Study Physician and has worked with a team which has successfully conducted International Maternal, Paediatric, Adolescents AIDS Clinical Trials (IMPAACT), AIDS Clinical Trials (ACTG) and HIV Prevention Trials Network (HPTN) clinical trials. He was Gaborone Clinical Research Site (CRS) leader from 2016 to 2022 and Molepolole CRS Leader from 2020 to 2023. Currently Dr. Masheto is the BHP Deputy Chief Executive Officer, CTU Coordinator, and the IMPAACT Network Project Leader/Principal Investigator (PI). Dr. Masheto is also a Co-Investigator for ACTG and HPTN studies. Dr Masheto graduated from Ross University School of Medicine in 2007 with an MD, and from Stellenbosch University in 2012 with Post Graduate Diploma in Family Medicine. He is enrolled to Masters (MSc) in Clinical Epidemiology at the London University’s London School of Hygiene and Tropical Medicine. Dr. Masheto’s interests are in Infectious Diseases and Non-communicable (with a focus in Cardiovascular Diseases) Clinical Research, Infectious Disease Epidemiology and Management with a focus on design, modelling, implementation, monitoring and evaluation of HIV/AIDS and TB prevention, care/support, treatment programs, and PMTCT interventions. He is also interested in research for HIV Cure and he is a fellow for International AIDS Society (IAS) 2018 Academy-for-Cure Research.